Sergio Fazio
About
Sergio Fazio is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Sergio Fazio has authored 143 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Surgery, 41 papers in Endocrinology, Diabetes and Metabolism and 29 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Sergio Fazio's work include Lipoproteins and Cardiovascular Health (82 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (37 papers) and Pharmaceutical Economics and Policy (17 papers). Sergio Fazio is often cited by papers focused on Lipoproteins and Cardiovascular Health (82 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (37 papers) and Pharmaceutical Economics and Policy (17 papers). Sergio Fazio collaborates with scholars based in United States, Canada and France. Sergio Fazio's co-authors include Michael D. Shapiro, Hagai Tavori, MacRae F. Linton, Pratik B. Sandesara, Salim S. Virani, Robert S. Rosenson, M. John Chapman, Marc S. Sabatine, Robert P. Giugliano and Chris Guerin and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
In The Last Decade
Sergio Fazio
136 papers receiving 7.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sergio Fazio United States | 44 | 4.6k | 2.3k | 1.9k | 1.4k | 1.4k | 143 | 8.0k | ||
| Fernando Civeira Spain | 43 | 4.9k 1.1× | 2.4k 1.1× | 1.9k 1.0× | 686 0.5× | 1.4k 1.0× | 286 | 8.0k | ||
| Ioanna Gouni‐Berthold Germany | 37 | 4.1k 0.9× | 1.8k 0.8× | 1.6k 0.8× | 749 0.5× | 1.2k 0.8× | 156 | 7.5k | ||
| Maurizio Averna Italy | 45 | 5.2k 1.1× | 2.9k 1.3× | 2.8k 1.5× | 823 0.6× | 1.2k 0.9× | 288 | 9.6k | ||
| Gérald Luc France | 46 | 3.1k 0.7× | 2.6k 1.1× | 3.0k 1.6× | 994 0.7× | 1.8k 1.3× | 88 | 9.1k | ||
| G. Kees Hovingh Netherlands | 52 | 7.4k 1.6× | 4.2k 1.8× | 2.7k 1.4× | 1.2k 0.9× | 1.8k 1.3× | 204 | 11.8k | ||
| Brian A. Ference United States | 29 | 3.6k 0.8× | 2.0k 0.9× | 1.6k 0.8× | 510 0.4× | 804 0.6× | 67 | 6.4k | ||
| Michael Szarek United States | 34 | 3.9k 0.9× | 3.3k 1.5× | 2.4k 1.2× | 695 0.5× | 1.0k 0.7× | 127 | 7.4k | ||
| Jan Albert Kuivenhoven Netherlands | 52 | 6.0k 1.3× | 4.4k 1.9× | 2.8k 1.5× | 1.1k 0.8× | 2.2k 1.6× | 157 | 10.5k | ||
| Marianne Benn Denmark | 43 | 4.1k 0.9× | 3.3k 1.4× | 2.6k 1.4× | 488 0.3× | 907 0.7× | 121 | 8.6k | ||
| Philippe Lesnik France | 34 | 2.6k 0.6× | 1.6k 0.7× | 1.1k 0.6× | 1.5k 1.1× | 1.1k 0.8× | 89 | 5.9k |
Countries citing papers authored by Sergio Fazio
Since
Specialization
Citations
This map shows the geographic impact of Sergio Fazio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio Fazio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio Fazio more than expected).
Fields of papers citing papers by Sergio Fazio
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sergio Fazio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio Fazio. The network helps show where Sergio Fazio may publish in the future.
Co-authorship network of co-authors of Sergio Fazio
This figure shows the co-authorship network connecting the top 25 collaborators of Sergio Fazio. A scholar is included among the top collaborators of Sergio Fazio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergio Fazio. Sergio Fazio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Schwartz, Gregory G., Michael Szarek, J. Wouter Jukema, et al.. (2025). Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial. Diabetes Care. 48(4). 596–604.
2.
Bossuyt, Patrick M., J. Wouter Jukema, L. Renee Ruhaak, et al.. (2025). Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. Arteriosclerosis Thrombosis and Vascular Biology. 45(11). 2111–2123.
3.
Pacheco-Velázquez, Silvia Cecilia, Carlota Oleaga, Bastian Ramms, et al.. (2025). LDL-Bound PCSK9 Has a Slower Clearance Kinetic and Higher Use for HSPGs Than Free-PCSK9—Brief Report. Arteriosclerosis Thrombosis and Vascular Biology. 45(9). 1565–1573.
4.
Szarek, Michael, Philippe Gabríel Steg, J. Wouter Jukema, et al.. (2024). Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES. European Journal of Preventive Cardiology. 31(10). e75–e78.
5.
Ferri, Nicola, Massimiliano Ruscica, Sergio Fazio, & Alberto Corsini. (2024). Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. Journal of Clinical Medicine. 13(4). 943–943.
6.
Schwartz, Gregory G., Michael Szarek, Deepak L. Bhatt, et al.. (2023). Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. European Heart Journal.
7.
Szarek, Michael, J. Wouter Jukema, Deepak L. Bhatt, et al.. (2023). Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. Circulation. 149(3). 192–203.
8.
Chung, Dominic W., Koya Ozawa, Reheman Adili, et al.. (2023). Low-density lipoprotein promotes microvascular thrombosis by enhancing von Willebrand factor self-association. Blood. 142(13). 1156–1166.
9.
Mohammadi, Kusha, Gregory G. Schwartz, Philippe Gabríel Steg, et al.. (2023). Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Medicine. 12(16). 16859–16868.
10.
Plubell, Deanna L., Phillip A. Wilmarth, Wayne M. Clark, et al.. (2020). High-Density Lipoprotein Carries Markers That Track With Recovery From Stroke. Circulation Research. 127(10). 1274–1287.
11.
Oleaga, Carlota, Joshua Hay, Larry L. David, et al.. (2020). Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. Journal of Lipid Research. 62. 100003–100003.
12.
Zhou, Ye, et al.. (2019). A neutral lipid-enriched diet improves myelination and alleviates peripheral nerve pathology in neuropathic mice. Experimental Neurology. 321. 113031–113031.
13.
Tavori, Hagai, Alexandra M Fenton, Deanna L. Plubell, et al.. (2019). Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity. The Journal of Clinical Endocrinology & Metabolism. 104(10). 4793–4803.
14.
Zhu, Lin, Christopher H. Emfinger, Bryan A. Parks, et al.. (2018). CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet. Diabetes. 67(12). 2494–2506.
15.
Fazio, Sergio, David Robertson, Tenshang Joh, et al.. (2017). Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin. Cardiovascular Therapeutics. 36(1).
16.
Norata, Giuseppe Danilo, Hagai Tavori, Angela Pirillo, Sergio Fazio, & Alberico L. Catapano. (2016). Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovascular Research. 112(1). 429–442.
17.
Kabagambe, Edmond K., Suzanne E. Judd, James C. Slaughter, et al.. (2015). Abstract P044: Alcohol Consumption, Statin Use and Risk of All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort. Circulation. 131.
18.
Kaseda, Ryohei, Kathy Jabs, Tracy E. Hunley, et al.. (2014). Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism. 64(2). 263–273.
19.
Lewis, Terry L., Dongfeng Cao, Hailin Lu, et al.. (2010). Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease. Journal of Biological Chemistry. 285(47). 36958–36968.
20.
Zhang, Ji, Sergio Fazio, & Robert W. Mahley. (1994). Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.. Journal of Biological Chemistry. 269(18). 13421–13428.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Fernando Civeira Breakdown of academic impact, for papers by Ioanna Gouni‐Berthold Breakdown of academic impact, for papers by Maurizio Averna Breakdown of academic impact, for papers by Gérald Luc Breakdown of academic impact, for papers by G. Kees Hovingh Breakdown of academic impact, for papers by Brian A. Ference Breakdown of academic impact, for papers by Michael Szarek Breakdown of academic impact, for papers by Jan Albert Kuivenhoven Breakdown of academic impact, for papers by Marianne Benn Breakdown of academic impact, for papers by Philippe Lesnik